



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 7474

|   |   |                                      |  |  |                                    |
|---|---|--------------------------------------|--|--|------------------------------------|
| <b>SERIAL NUMBER</b><br>10/522,718  | <b>FILING OR 371(c)<br/>DATE</b><br>01/28/2005<br><b>RULE</b>   | <b>CLASS</b><br>514                  | <b>GROUP ART UNIT</b><br>1614  | <b>ATTORNEY<br/>DOCKET NO.</b><br>2005-0136A |                                    |
| <b>APPLICANTS</b><br>Minoru Moriya, Tsukuba-shi, JAPAN;<br>Akio Kanatani, Tsukuba-shi, JAPAN;<br>Hisashi Iwaasa, Tsukuba-shi, JAPAN;<br>Akane Ishihara, Tsukuba-shi, JAPAN;<br>Takehiro Fukami, Tsukuba-shi, JAPAN;   |   |                                      |  |  |                                    |
| <b>** CONTINUING DATA *****</b><br>This application is a 371 of PCT/JP03/09610 07/29/2003   |   |                                      |  |  |                                    |
| <b>** FOREIGN APPLICATIONS *****</b><br>JAPAN 2002-220905 07/30/2002  |   |                                      |  |  |                                    |
| Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no<br>35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after<br>met Allowance<br>Verified and Acknowledged<br>Examiner's Signature _____ Initials _____ |   | <b>STATE OR<br/>COUNTRY</b><br>JAPAN | <b>SHEETS<br/>DRAWING</b><br>1   | <b>TOTAL<br/>CLAIMS</b><br>27                | <b>INDEPENDENT<br/>CLAIMS</b><br>1 |
| <b>ADDRESS</b><br>000513  |   |                                      |  |  |                                    |
| <b>TITLE</b><br>Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient  |   |                                      |  |  |                                    |
| <b>FILING FEE<br/>RECEIVED</b><br>1250  | FEES: Authority has been given in Paper<br>No. _____ to charge/credit DEPOSIT ACCOUNT<br>No. _____ for following: |                                      | <input type="checkbox"/> All Fees<br><input type="checkbox"/> 1.16 Fees ( Filing )<br><input type="checkbox"/> 1.17 Fees ( Processing Ext. of<br>time )<br><input type="checkbox"/> 1.18 Fees ( Issue )<br><input type="checkbox"/> Other _____<br><input type="checkbox"/> Credit |  |                                    |